ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015
Salivary gland myoepithelial carcinoma.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoingFrontiers in oncology · 2026Article
- Myoepithelial Carcinoma Ex-Pleomorphic Adenoma Exposing a RET Germline Mutation: A Rare Genetic Event.Head and neck pathology · 2025Article
- Myoepithelial carcinoma of submaxillary gland: A case report.Oncology letters · 2025Article
- Successful surgical interventions for a giant and complicated myoepithelial carcinoma: a case report.Archives of craniofacial surgery · 2024Article
- Myoepithelial carcinoma of major salivary glands: Analysis of population-based clinicopathologic and prognostic features.Translational oncology · 2022Article
- [Myoepithelial carcinoma of the parotid gland: a rare tumor with diagnostic challenges].Wiener medizinische Wochenschrift (1946) · 2022Article
- Prognostic analysis and establishment of a nomogram in patients with myoepithelial carcinoma of the salivary gland: A population-based study.Laryngoscope investigative otolaryngology · 2022Article
- Malignant Myoepithelioma of the Head and Neck: Demographics, Clinicopathological Characteristics, Treatment, and Prognosis.Frontiers in oncology · 2022Article
- Primary Parotid Tumor Thrombosis: Immunohistologic Features and Awareness of Metastatic Potential.Cureus · 2021Article
- Myoepithelial Tumors of Salivary Gland: A Clinicopathologic and Immunohistochemical Study of 15 Patients with MIB-1 Correlation.Head and neck pathology · 2021Article
- Two cases of rare thyroid malignancy-case report.Gland surgery · 2021Article
- Invasive myoepithelial carcinoma ex pleomorphic adenoma of the major salivary gland: two case reports.BMC cancer · 2016Article
- Parotid Myoepithelial Carcinoma in a Pediatric Patient with Multiple Recurrences: Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivary gland myoepithelial carcinoma (MC) or malignant myoepithelioma is a rare entity. MC usually presents as a slow-growing painless mass arising in the parotid gland, but may involve other salivary glands. This tumour may be particularly locally aggressive, but its clinical and biological features are not yet fully understood. MC may arise from pre-existing benign lesions, such as pleomorphic adenomas or benign myoepitheliomas, or may arise de novo. It usually affects patients over 50 years old, with no gender preference. Because it is often asymptomatic, the presentation and diagnosis can be delayed by months, even years. The current WHO classification considers MC to be an intermediate- to high-grade malignancy. Other published data suggest it is likely to be a high-grade neoplasm, consistent with its aggressive behaviour. Its epidemiology, histopathological features, immunohistochemical profile, clinical behaviour and optimal management are not well understood. Following review of the current literature we aim to address these.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.